Encora Health combines in-depth medical expertise , evidence-based GLP-1 therapy , and a deep understanding of Austins unique wellness culture
Bottom line: Oral GLP-1 supplements have a more substantiated evidence base than patches
Only 13 state Medicaid programs currently cover GLP-1 medications for obesity treatment, and several states have recently pulled back coverage due to budget pressures
Moreover, the SUSTAIN trials, which studied the effects of semaglutide in those with T2DM, also demonstrated significant improvement in risk factors, with a substantial 26% relative reduction in cardiovascular events such as nonfatal myocardial infarction and stroke [13,14,29]
In some cases, its better for patients to be heard, evaluated, and just be reassured that things will get better with time, Garshick said
1,2 The use of these medications is rapidly expanding as they gain in popularity and receive FDA approvals across multiple disease states